AINDEX
Markets

Eikon Therapeutics, Inc. (EIKN)

EIKNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)

$5.98

-0.0600 (-0.99%) today

Closed, Nov 13, 4:00 PM ET

-0.99% 1D
Market cap
$324.03m
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$5.01 to $17.40
Average volume
–
Previous close
$6.04

Earnings

next estimate $-1.88

Next report

Mar 2026

-67.3%

Jun 2026

-1.2%

Sep 2026

+8.6%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue––––
Gross profit––––
Operating income-$83.17m-$87.34m-$93.39m-$90.55m
Net income-$79.66m-$82.96m-$88.41m-$86.11m

News

8 latest

The company

Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-GS
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.